Sponsor content

Therapeutic genome editing

Precision BioSciences is harnessing its next-generation genome editing platform, ARCUS, to develop a pipeline of cell-based immunotherapies for cancer and autoimmune disease, as well as gene therapies for rare genetic disorders. The company is looking for uniquely suited partners to aid in these efforts.

1
0
Upvote 1 Comment
Page of
Go to the profile of Precision Biosciences

Precision Biosciences

Precision utilizes a proprietary genome editing method called ARCUS combined with a team made up of some of the leading minds and pioneers in genome editing in an effort to overcome cancers, cure genetic diseases, and enable the development of safer, more productive food sources.

No comments yet.